Bone metastases are secondary malignant tumors in bone caused by spread from a primary cancer elsewhere in the body. They are common in advanced malignancy and can cause pain, fractures, spinal cord compression, hypercalcemia, and major quality-of-life decline.
Clarity Pharmaceuticals announced preliminary SECuRE trial results showing 74% of participants achieved PSA25 and 81% disease control with 8 GBq 67Cu-SAR-bisPSMA. A 76-year-old patient achieved undetectable disease after two cycles, and shares rose 14%.
More than 80% of U.S. physicians use AI in their work. AI is revealing new cardiac biomarkers and speeding drug discovery, with the healthcare AI market projected to reach $505.6 billion by 2033—but studies warn of bias and eroding critical thinking.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
Biocon has launched denosumab biosimilars Bosaya and Aukelso in the United States following FDA approval with interchangeable designation. The products target osteoporosis and bone metastases, entering a market where denosumab products generated approximately $5 billion in U.S. sales in 2024. The launch represents a strategic expansion of Biocon's biosimilar portfolio amid competitive market conditions.
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
The FDA approved multiple denosumab biosimilars in late 2025 and issued REMS safety updates emphasizing severe hypocalcemia risk in patients with advanced chronic kidney disease, including reported hospitalizations and fatalities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07733193 |
Impact of Prophylactic Bone Radiation Therapy in Patients With Bone Metastases. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07687225 |
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases |
NOT_YET_RECRUITING | NA |
| NCT07540650 |
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers |
NOT_YET_RECRUITING | PHASE2 |
| NCT07537972 |
Denosumab Strategy for Liver Cancer With Bone Metastases |
NOT_YET_RECRUITING | PHASE2 |
| NCT07429422 |
SBRT Technique Implementation for Spinal Metastases Irradiation |
RECRUITING | NA |
| NCT07391410 |
Registry for Bone Metastases |
RECRUITING | |
| NCT07202273 |
Simulation-Free, Single-Fraction Palliative Radiation Therapy for Treatment of Bone Metastases |
RECRUITING | NA |
| NCT07196995 |
Validation of Whole Body PET/CT Foundation Model |
NOT_YET_RECRUITING | |
| NCT07185958 |
Dual Energy CT - a Tool for Delineation of Tumor and Organs at Risk in Radiotherapy |
NOT_YET_RECRUITING | |
| NCT07146074 |
Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases |
RECRUITING | NA |
